The Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with type 2 diabetes who are at high risk for those events. Eli Lilly announced the approval Friday morning.
Mounjaro, the brand name for tirzepatide, was already approved as an addition to diet and exercise to improve blood sugar in adults and children aged 10 and older with type 2 diabetes. Lilly describes it as the most-prescribed branded type 2 diabetes medication for adults in the United States. The new indication adds heart protection to the label of a drug many Americans already inject weekly.
